Leukotriene (LT) B4 is a major chemical activator of PMN. Inhibitory effects of oral administration of docosahexaenoic acid (DHA) on LTB4 synthesis by PMN are known. We intravenously infused tridocosahexaenoyl-glycerol (DHA-TG) emulsion into rabbits in three different doses, namely 0.8, 0.4, or 0.2 g DHA/kg, and investigated the changes in LTB4/1 production by ionophore-activated PMN. The averaged LTB4 production by PMN was significantly reduced to 57 and 59% of baseline at 6 h after the infusion of 0.8 and 0.4 g DHA/ kg, respectively (P < 0.05), but not after the infusion of 0.2 g DHA/kg or 0.8 g soybean oil/kg. The combined concentrations of both DHA and eicosapentaenoic acid in the PMN phospholipid fraction were significantly increased at 6 h after the infusion of 0.8 or 0.4 g DHA / kg but not after the infusion of0.2 g DHA / kg or 0.8 g soybean oil / kg. Oral administration of 0.8 g DHA/kg did not increase DHA or eicosapentaenoic acid in the PMN phospholipid fraction and did not decrease LTB4
Introduction
Leukotriene (LT) B4 is a metabolite of AA (20:4n-6 ) through the 5-lipoxygenase pathway ( 1 ) and a major activator ofleukocytes inducing chemotaxis, aggregation, degranulation, and adhesion (2, 3) . Excess production of LTB4 may exacerbate pathophysiological states such as inflammation, asthma, arthritis, and psoriasis (2) (3) (4) . According to recent studies, LTB4 is also related to the reperfusion injury (5, 6) and cardiac arrhythmias (7) in acute myocardial infarction. Indeed, in experimental infarction induced by occlusion and reperfusion of coronary arteries, a 5-lipoxygenase inhibitor is reported to be able to reduce infarct size (6) and cardiac arrhythmias (8) .
Receivedfor publication 18 May 1992 and in revisedform 2 April 1993. Docosahexaenoic acid (22:6n-3, DHA),' which is a major polyunsaturated fatty acid (PUFA) of fish oil like eicosapentaenoic acid (20: 5n-3, EPA), is found in retina, sperm, and heart of land animals, as the major fatty acid component in phospholipids (9) . DHA is probably essential for the functional development of nervous system (10), including retina ( 11 ). DHA has some other effects such as depression ofplatelet aggregation ( 12) , augmentation of the efficacy of anticancer drugs ( 13, 14) , and prevention of arrhythmia ( 1 5 ).
Effects of DHA administration on LTB4 synthesis were discussed in several studies (16) (17) (18) (19) (20) . Lokesh et al. ( 19) reported that the LTB4 and LTC4 production by peritoneal macrophages of mice was reduced by dietary supplementation of a DHA-rich fish oil. However, a period as long as 10 d of oral administration of DHA might be necessary to reduce LTB4 production ( 19) . The effect of this type of intervention is not rapid enough for management of acute diseases related to LTB4. Hamazaki et al. (21 ) developed tridocosahexaenoyl-glycerol (DHA-TG) emulsion previously and demonstrated that two intravenous infusions of the emulsion into rabbits completely prevented sudden death induced by intravenous injection of AA. However, the effect of the intravenous infusion of the emulsion on LTB4 synthesis has not yet been investigated.
In the present study, we show that LTB4 production by PMN was reduced by about one-half 6 h after the intravenous infusion of DHA-TG emulsion into rabbits.
Methods
Experimental design Experiment 1. Male Japanese white rabbits weighing 3.0-3.5 kg were used in the present study. They were caged separately under standard conditions of temperature, lighting, and water supply and were fed ad libitum a commercial standard rabbit diet (RM-3; Funabashi Farms, Chiba, Japan) containing soybean oil as the fat component before and throughout the experiment. A group of five rabbits was infused with DHA-TG emulsion (0.8 g DHA/kg) through ear veins over 15 min (0.8-g DHA group). Another group of five rabbits (control group) was infused with a commercial soybean oil emulsion (Intralipid; KabiVitrum AB, generously donated by Otsuka-Pharmaceuticals, Tokyo, Japan) (0.8 g soybean oil/kg) in the same manner. 10 ml of blood was obtained with a heparinized syringe from central ear arteries I wk before, and 6 and 24 h after the infusion ofeither emulsion for analysis of the LTB4/5 production by PMN and fatty acid analysis of plasma. Additional heparinized blood samples were obtained 1 wk before and 24 h after the infusion for fatty acid analysis of PMN.
To investigate whether LTB4 production by rabbit PMN was reduced by smaller doses of DHA-TG emulsion, we used two smaller doses (0.4 and 0.2 g DHA/kg) and measured LTB4/5 production by PMN. Five rabbits were infused with 0.4 g/kg DHA-TG (0.4-g DHA group). Another five rabbits were infused with 0.2 g/kg DHA-TG (0.2-g DHA group). Blood samples for analysis of the LTB4 production by PMN and fatty acid composition of plasma were similarly obtained 1 wk before, and 6 and 24 h after the infusion. Experiment 2. To clarify the changes in the fatty acid composition of PMN at 6 h after the infusion of DHA or soybean oil, another 16 rabbits were similarly infused; 4 rabbits for the 0.8-g soybean oil (control) group and 12 rabbits for the 0.8-, 0.4-, and 0.2-g DHA groups (4 rabbits per group). Their PMN both 1 wk before and 6 h after the infusion were obtained for fatty acid analysis.
Experiment 3. Efficacy of the oral administration of DHA-TG emulsion was tested in another five rabbits. Since we had run out of DHA-TG emulsion at the end ofexperiment 2, we made a new batch of DHA-TG emulsion for this experiment. The materials and methods for preparing emulsion were exactly the same as in the case of experiments 1 and 2 (see below) except that a different batch of DHA-TG (purer than before) was used. The five rabbits were orally administered DHA-TG emulsion in a dose of 0.8 g DHA/kg through a gastric tube over 5 min without fasting as in experiments I and 2. Their PMN 1 wk before, and 6 and 24 h after the oral administration were obtained for LTB4/5 production. Plasma was also obtained at the same time points for its fatty acid analysis. Blood samples for analysis of fatty acid composition in PMN phospholipid were also obtained at 6 and 24 h after the oral administration.
Isolation ofPMN 10 ml of blood sample obtained as described above was mixed with 10 ml of6% (vol/ vol) dextran (mol wt, 180,000; Pharmacia LKB Biotechnology Inc., Uppsala, Sweden) in saline and allowed to sediment for 60 min at room temperature. The supernatant was applied to 10 ml of Ficoll (Pharmacia LKB Biotechnology Inc.)-Conray (Daiich-Seiyaku, Tokyo, Japan) solution and was centrifuged at 450 g for 20 min at 4VC. The contaminating erythrocytes were removed by hypotonic lysis with ice-cold distilled water, and isotonicity was restored by the addition ofa 1.8% NaCl solution. The suspension was again centrifuged, and the pellet was finally suspended in HBSS. The final suspension contained 0.5-1.5 x 107/ml PMN measured by a hemocytometer. The viability was checked by a trypan blue exclusion test and always was > 95%.
Measurement of LTB415 production by PMN PMN suspension (0.8 ml) was preincubated at 37°C for 10 min, and then incubated with 10 tM calcium ionophore A23 187 (Sigma Chemical Co., St. Louis, MO) at 37°C for 10 min. The incubation was terminated by the addition ofa half volume ofice-cold ethanol. 200 ng PGB1 (Sigma Chemical Co.) was added to the incubation mixture as an internal standard. We had confirmed in a preliminary experiment that the PGB, was well separated by reverse-phase HPLC from LTB4/5. The mixture was centrifuged at 1,700 g for 15 min at 4°C. The supernatant was acidified with 0.1 N HCl to pH 3 and applied to a prewashed (20 ml ethanol and 20 ml water) ODS-silica minicolumn (Toyopak; Tosoh Corporation, Tokyo, Japan). The column was washed with 20 ml 15% ethanol-aqueous solution, 20 ml water, 20 ml petroleum ether, and, finally, 6 ml ethyl acetate. Arbor, MI). In preliminary experiments immunoreactivity offractions of retention times of LTB4/5 to anti-LTB4 antibody (Daiichi-Kagaku, Tokyo, Japan) was confirmed. Amount of LTB4/1 was determined with comparison to area of peaks of standard LTB4/5 after the correction of recovery using PGB1 (internal standard). The recovery of LTB4/5 and PGB1 from this procedure was -90%. Preparation ofDHA-TG emulsion Sardine oil was extracted from edible parts ofsardine. After separation of saturated lipids by crystallization at -70'C, a PUFA-rich triglyceride mixture was saponified and then methylated (22) . Methyl esters of PUFAs were separated to obtain a DHA methyl ester fraction by HPLC (23) . Free DHA, which was obtained by hydrolysis of DHA methyl ester, and glycerol were reacted, and DHA-TG was separated (21 ). The fatty acid composition of the DHA-TG for experiments I and 2 was 95% DHA, 2% EPA, 0.5% docosapentaenoic acid (22: 5n-3), 0.2% oleic acid ( 18: 1n-9), and 0.12% AA. The purity ofDHA-TG for experiment 3 was 98%. DHA-TG was fortified with 0.2% a-tocopherol and emulsified with egg yolk lecithin according to Geyer et al. (24) . 100 ml of DHA-TG emulsion contained 10 g DHA-TG, 1.2 g egg yolk lecithin as an emulsifier, and 2.5 g glycerol for osmotic pressure. The fatty acid composition of the egg yolk lecithin was as follows: 36% palmitic acid (16:0), 23% oleic acid, 15% stearic acid (18:0) , 11% linoleic acid (I18:2n-6), 4% AA, and 4% DHA. 100 ml of the commercial soybean oil emulsion contained 10 g soybean oil, 1.2 g egg yolk lecithin, and 2.5 g glycerol. The fatty acid composition of the soybean oil used was as follows: 59% linoleic acid, 22% oleic acid, 8% palmitic acid, 8% a-linolenic acid ( 18:3n-3), and 3% stearic acid. The fatty acid composition of the egg yolk lecithin of this emulsion was similar to that used in the DHA emulsion.
Analysis offatty acid composition ofplasma and PMN Experiment 1. Fatty acid composition of plasma was analyzed 1 wk before, and 6 and 24 h after the infusion. That ofPMN was analyzed 1 wk before and 24 h after the infusion only in the 0.8-g DHA and control groups. In experiment 1, we did not measure fatty acid composition of PMN 6 h after the infusion so as not to make the animals anemic; it would have been necessary to take another 10 ml blood sample for the fatty acid measurement of PMN, and anemia might have modulated PMN population and functions. We did not measure fatty acid composition of PMN in the 0.4-and 0.2-g DHA group either, because there were no significant changes in the fatty acid composition of PMN between before and 24 h after DHA infusion even in the highest dose group. Experiment 2. To obtain enough PMN and to analyze fatty acid composition of their phospholipid (PL) and FFA fractions at 6 h after the infusion of 0.8, 0.4, or 0.2 g DHA/kg, or 0.8 g soybean oil/kg, blood samples were collected before and 6 h after the infusion in a separate experiment. Experiment 3. Fatty acid composition ofplasma was analyzed 1 wk before, and 6 and 24 h after the oral administration ofDHA-TG emulsion. Blood samples for fatty acid composition in the PMN PL fraction were not obtained before the oral administration because at this stage we were very sure that our rabbits without any treatment did not have even trace amounts of DHA or EPA at all in their PMN. Effects of anemia might also be reduced in this way.
Total lipids of plasma or PMN suspended in HBSS were extracted according to Folch et al. (25) after the addition of 1,2-dipentadecanoylphosphatidylcholine, tripentadecanoyl-glycerol, and free pentadecanoic acid ( 15:0) as internal standards for the quantitative measurement of fatty acids of respective lipid fractions. PL, TG, and FFA were separated by TLC on silica gel plates (0.25-mm Silica Gel 60; Merck, Derstadt, Germany) with petroleum ether/diethyl ether/acetic acid (80:20:1 ) as a solvent system for plasma samples. Fatty acids of these fractions were transmethylated with 6% H2SO4 in methanol at 70°C for 45 min. Fatty acid methyl esters were analyzed with a gas chromatograph (model GC-14A; Shimadzu) equipped with an capillary column (0.32 mm i.d. x 30 m, model SP-2330; Supelco, Bellefonte, PA). The injection port was at 2500C; column temperatures were programmed at 1600C for 10 min, from 160 to 200'C at 40C/min, and maintained; detection was by flame ionization. Helium was used as a carrier gas with an inlet pressure of 0.56 kg/cm2.
Statistical analysis
Experiments I and 2. Data are expressed as means±SD. The reduction of LTB4 production by PMN after DHA infusion was analyzed by two methods. The reduction of LTB4 production at 6 and 24 h was compared with baseline within the same groups by a paired t test with Bonferroni's adjustment after analysis ofvariance (ANOVA). Second, the percentage of LTB4 production at 6 and 24 h compared with baseline was compared with that of the control group at the same time points by an unpaired t test with Bonferroni's adjustment after AN-OVA. Changes in fatty acid composition were similarly compared. The comparison of LTB5 production among the DHA-infused groups was performed by the unpaired t test with the adjustment after ANOVA. P < 0.05 was significant. Experiment 3. Since this experiment was performed completely separately from experiments 1 and 2 with a different batch ofDHA-TG emulsion, no statistical comparison between experiment 3 and experiments 1 or 2 was performed. However, changes in fatty acid composition and LTB4/5 production were statistically analyzed within this experiment as described above.
Results

Experiment I
LTB415 production by PMN. The changes in LTB415 production by PMN in the 0.8-g DHA group are shown in Fig. 1 . The 40- averaged LTB4 production at 6 h after the infusion was significantly reduced to 57% of baseline value (from 26.0±4.4 to 14.1±3.7 ng/ 107 PMN, P < 0.05). This reduction was also significantly different (P < 0.025) from changes in the control group at 6 h ( 1 18%, see Fig. 5 ). The production ofLTB4 at 24 h after the infusion was 81% ofbaseline value (20.9±6.6 ng/ 107 PMN). At baseline, LTB5 production was below the detection limits (-1 ng/ 107 PMN). The LTB5 production at 6 h after the infusion (5.6±3.1 ng/ 107 PMN) was about a half amount of LTB4 production at the same time point. The production at 24 h after the infusion was almost the same as that at 6 h after the infusion (5.7±3.1 ng/ I07 PMN).
The changes in LTB4 production by PMN in the control group are shown in Fig. 2 . There were no significant differences between before and after the infusion of the soybean oil emulsion in LTB4 production (before, 25 .2±3.9 ng/ 107 PMN; at 6 h after the infusion, 29.2±9.7 ng/ 107 PMN; and at 24 h after the infusion, 27.5±5.4 ng/ 107 PMN). LTB5 production was below the detection limits both before and after the infusion.
The changes in LTB4/1 production by PMN in the 0.4-and 0.2-g DHA groups are shown in Figs. 3 and 4, respectively. The LTB4 production in the 0.4-g DHA group was significantly reduced at 6 h after the infusion (from 24.6±6.1 to 14.2±3.7 ng/ 107 PMN, 59%, P < 0.05); this reduction was also significantly different from the control group at the same time point (P < 0.025). There were no significant differences in LTB4 production before and after the infusion in the 0.2-g DHA group (before, 25.4±8.4 ng/ 107 PMN; at 6 h after the infusion, infusion in the 0.4-or 0.2-g DHA group was detectable but smaller than that after the infusion in the 0.8-g DHA group.
The comparison of percent baseline value of LTB4 production at 6 h after the infusion among the three DHA and control groups is shown in Fig. 5 . The comparison of percent baseline value of LTB4 production at 24 h after the infusion revealed that there were no significant differences among the three DHA and control groups (0.8-g DHA group, 81±26%; 0.4-g DHA group, 102±17%; 0.2-g DHA group, 99±17%; and control group, 110±24%). LTB5 production after the infusion in the 0.8-g DHA group was significantly greater than that in the 0.2-g DHA group at either time point (at 6 h after the infusion, 5 because ofa high linoleic acid concentration in the soybean oil used and were significantly decreased in the plasma PL fraction because of a low linoleic acid concentration in the egg yolk lecithin used. Oleic acid concentrations in the plasma PL and FFA fractions were also significantly increased at 6 h after the infusion of soybean oil and then decreased in the PL fraction at 24 h after the infusion. DHA concentrations in the plasma PL fraction were slightly increased at 6 h after the infusion of soybean oil and decreased at 24 h after the infusion. There were no significant changes in the fatty acid composition ofthe total PL fraction ofPMN at 24 h after the infusion in either the 0.8-g DHA or the control group (data not shown).
The changes in the plasma lipid concentrations and in the fatty acid composition of plasma in the 0.4-and 0.2-g DHA groups (data not shown) were similar to those of the 0.8-g DHA group except for the FFA fractions.
The free DHA concentrations in plasma at 6 h after the infusion in the three DHA and control groups are shown in Fig.  6 . Free DHA was not detected in plasma before the infusion. The averaged concentration of plasma-free DHA was drastically increased 6 h after the infusion in the 0.8-g DHA group and then decreased thereafter (at 6 h after the infusion, 20.2±17.1 MM; not significantly different from baseline because ofwide variations; and at 24 h after the infusion, 3.1 ± 1.5 gMM). Those at 6 h after the infusion were significantly different from the control group (P < 0.025). The averaged concentrations of plasma-free DHA at 6 h after the infusion in the 0.4 g DHA group were slightly increased (at 6 h after the infusion, 4.6±3.4 MM; and at 24 h after the infusion, 1.1±0.9 MM). There was no detectable DHA in the plasma FFA fraction either before or after the infusion in the 0.2-g DHA or control group.
Experiment 2
The fatty acid composition of PMN at 6 h after the infusion was measured in experiment 2. The DHA, EPA, and combined (DHA + EPA) concentrations in the total PL fraction of PMN at 6 h after the infusion in the three DHA and control groups are shown in Fig. 7 . Neither DHA nor EPA was detected in the PL fraction of PMN before the infusion. DHA and EPA concentrations in the PL fraction of PMN at 6 h after DHA infusion were increased in a dose-dependent manner; those of the 0.8-g DHA group were significantly increased compared with baseline and also with those ofthe control group, but not in the other DHA groups. The combined concentrations of both DHA and EPA at 6 h after the infusion were significantly increased in the 0.8-and 0.4-g DHA groups, but not in the 0.2-g DHA group, compared with baseline. The combined concentrations of the 0.8-g DHA group were significantly increased compared with the control group; those of the 0.4-g DHA group tended to be increased (P = 0.061 ) compared with the control group. The AA concentrations in the PL fraction of PMN in the three DHA and control groups are shown in Fig. 8 . Those of the 0.8-and 0.4-g DHA groups were significantly reduced to 58±10 and 54±8% of their baseline 6 h after the infusion, respectively. Those of the 0.2-g DHA group were nonsignificantly reduced to 65±25% of baseline (P = 0.066) 6 h after the infusion. Those of the control group were not changed before and 6 h after the infusion. The reduction rates of AA concentrations in all the three DHA groups were significantly different from the changes in AA concentrations in the control group ( 123±27%, P < 0.025). Other major fatty acids were not significantly changed in the PL fraction of PMN at 6 h after the infusion.
Free DHA was not detected in PMN of any rabbits at 6 h after the infusion even in the 0.8-g DHA group.
Experiment 3 LTB4IS production by PMN. As shown in Fig. 9 , LTB4 production by PMN was not significantly affected by the oral administration ofDHA-TG emulsion in a dose of0.8 g DHA/kg. LTB5 production was not detected even after the oral administration. Table III . DHA concentrations in the plasma TG and PL fractions were markedly increased but not in the FFA fraction.
Neither DHA nor EPA was detected in the total PL fraction of PMN at 6 or 24 h after the oral administration except for a very small amount of DHA (0.19%) that was detected in one rabbit at 6 h after the administration.
For reference, we compared absolute amounts (jiM fatty acid equivalent) of DHA in plasma lipids between the intravenous and oral administration of DHA-TG emulsion in a dose of 0.8 g DHA/kg (Table IV) .
Discussion
The effects of DHA administration on in vitro ( 16, 18, 20) or ex vivo ( 17, 19) LTB4 production have been discussed in several studies. However, the methods of administration of DHA in these studies were either oral or in vitro. The present study first showed the effects of intravenous administration of DHA on ex vivo LTB4 production by PMN. Because the LTB4 production was not significantly altered after soybean oil infusion, the reduction of LTB4 production after the DHA infusion cannot be attributed to effects of infusion of a glycerol solution containing lecithin. It appears that DHA was responsible for this reduction.
There are several possible mechanisms of reduction in LTB4 production by DHA infusion. (a) Increased DHA and EPA in the total PL fraction ofPMN after DHA infusion probably competed with AA for phospholipase A2 and/or 5-lipoxygenase, especially in the 0.8-and 0.4-g DHA groups in which the combined concentrations of both DHA and EPA were significantly increased in the total PL fraction of PMN at 6 h after the infusion. (b) LTA4 hydrolase, which converted LTA4 to LTB4, might be inhibited by LTA5 (26) , which was synthesized from EPA. As shown in Figs. 1, 3, and 4 , the PMN production of LTB5, which was converted from LTA5, was produced by PMN ofthe DHA-infused groups in a dose-dependent manner, which suggests that reduction in LTB4 production in the DHA-infused groups might be at least partly due to LTA5 production. (c) The active pool of AA for LTB4 production in the PL fraction of PMN might be reduced after DHA infusion. As shown in Fig. 8 , the AA concentrations were significantly reduced in the PL fraction ofPMN in the 0. Before PMN were prepared for LTB415 production analysis, they had probably been circulating for hours in free DHA-rich plasma in the 0.8-and 0.4-g DHA groups. On the other hand, we did not detect free DHA in plasma at all at 6 h after the infusion in the 0.2-g DHA or control group (Fig. 6 ). These findings probably account for the significant changes in DHA, EPA, and AA concentrations in PMN and, hence, changes in LTB4 production in the 0.8-and 0.4-g DHA groups, but not in the 0.2-g DHA or control group. In this context, it is noteworthy that, according to The reason why we developed infusible DHA emulsion is that an instantaneous increase in plasma DHA concentrations by DHA infusion increases those in various tissues very quickly (27) so that DHA might rapidly take effect. However, we have not compared the two administration methods, namely oral and intravenous, by a similar experimental procedure yet. As shown in Fig. 9 , the oral administration of DHA-TG emulsion did not significantly reduce LTB4 production even in a dose of 0.8 g DHA/kg. As shown in Table III , the oral administration markedly increased DHA concentrations in the TG fraction at 6 h. However, the comparison of DHA concentrations in terms of millimoles of fatty acid equivalent (Table IV) indicates an unmistakable superiority of the intravenous infusion method to the oral administration, at least at 6 h after administration. The free DHA levels in plasma at 6 h after the oral administration were one-third of those of the 0.4-g DHA group at the same time point (Fig. 6 ). These very low free DHA levels in the oral group probably explain the failure for PMN to incorporate DHA into the PL fraction, resulting in stable LTB4 production as shown in Fig. 9 .
In experiments of oral administration of fish oils, which contained EPA and DHA, there was usually a reciprocal relationship between EPA, DHA, and AA (28) . However, this relationship is not always the case in single-administration experiments, whether intravenous (27) or oral (29) . In the present study, AA concentrations in the plasma lipid fractions were not reduced at 6 h after the administration of 0.8 g DHA/kg irrespective ofthe administration methods used (Tables I and III) . It is not exactly clear how administered DHA maintained or even increased plasma AA concentrations. However, the presence of AA (4%) in the lecithin for emulsification may partly explain a small upward deflection of AA concentrations in plasma.
Free EPA concentrations were significantly increased at 6 h after the infusion in the 0.8-g DHA group. This increment was partly due to contaminating EPA (2%) in the DHA-TG preparation for emulsification and partly due to the retroconversion of infused DHA (30, 31 (27) demonstrated that the infusion of DHA ethyl ester emulsion into rats increased the free DHA concentrations in plasma and heart from 0 to 8 and to 10 mol% in 1 h, respec- tively. Taken together with these results, it is likely that this quick method of increasing the free DHA concentrations in both plasma and tissues is useful for the prevention ofventricular fibrillation if used in the very early phase of acute myocardial infarction or during pending infarction. DHA infusion may also reduce myocardial damage because it probably prevents the accumulation of PMN induced by LTB4 production, which is intimately associated with the development of myocardial damage (5, 6). In our laboratory, Taki et al. (32) observed beneficial effects of DHA-TG emulsion on delayed-type hypersensitivity (DTH) in mice. We measured the swelling ofthe right hindleg footpads 24 h after the injection of sheep red blood cells (SRBC) into the footpads of SRBC-immunized mice and regarded the swelling as the DTH reaction. We found that the injection of DHA-TG emulsion into tail veins just before the SRBC challenge suppressed the DTH reaction almost completely. Consequently, DHA infusion may be beneficial for the prevention of acute allograft rejection, which is similar to the DTH reaction.
In addition, more recently we observed that acute inflammation in rat footpads induced by carrageenin was depressed by the injection of DHA-TG emulsion into rat tail veins just before the carrageenin injection into footpads and that the injection of DHA-TG emulsion was as effective as the injection of 225 mg/kg of aspirin DL-lysine (unpublished data). These beneficial effects of DHA emulsion, including what is described in the previous paragraph, are probably explained partly by its effect on LTB4 production.
The intravenous infusion of DHA into rabbits increased the DHA and EPA concentrations of plasma and PMN, reduced the AA concentrations of PMN, and thus significantly reduced LTB4 production by PMN by about one-half6 h afterward. However, a single oral administration of DHA did not increase the DHA or EPA concentrations of PMN and, consequently, did not modify LTB4 production by PMN. These re-sults suggest that the intravenous infusion of DHA-TG emulsion might be beneficial to patients who suffer from inflammatory diseases that are related to the acute elevation of LTB4 production.
